Skip to main content

Advertisement

SpringerLink
Log in

Extending the benefits of adjuvant therapy in early HR+ breast cancer

  • Optimizing Breast Cancer Patient
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The benefits of adjuvant tamoxifen are well documented, but therapy is limited to 5 years because of reports of an unfavorable risk: benefit profile in later years. However, the risk of relapse continues beyond the end of therapy. Before the MA.17 trial, no agent given after the standard 5 years of adjuvant tamoxifen had been shown to provide additional benefit, leaving women unprotected against the ongoing risk of late recurrences of breast cancer. In the MA.17 trial, starting letrozole within 3 months of completing tamoxifen significantly reduced the risk of relapse (including distant metastases) compared with placebo, and also significantly improved survival in patients who had node-positive disease at diagnosis. On the basis of data from the first interim analysis, the MA.17 trial was unblinded, and all patients in the placebo arm were offered letrozole: approximately two-thirds accepted. Early study unblinding left some important questions unanswered (including the long-term safety of extended adjuvant letrozole), but provided an opportunity to assess the benefits of starting letrozole after a prolonged period without active therapy. Even after a prolonged tamoxifen-free period, starting letrozole improved disease-free survival and distant disease-free survival, and reduced the occurrence of new, contralateral primary breast cancer, compared with observation and no active therapy. In subsequent intention-to-treat analyses, the benefit of letrozole persisted, despite a significant proportion of patients in the placebo arm having crossed over onto late extended adjuvant letrozole. In additional pre-unblinding, retrospective analyses derived from the core MA.17 data, the benefits of extended adjuvant letrozole increased with treatment duration, at least upto 4 years, and the efficacy of letrozole appeared to vary in defined patient subgroups. Current data strongly support the use of extended adjuvant letrozole to protect postmenopausal women with HR+ early breast cancer against the risk of late recurrence of disease, and suggest that all women should be considered for letrozole, even if several years have elapsed since tamoxifen was completed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Clemons M, Goss PE (2001) Mechanisms of disease: estrogen and the risk of breast cancer. N Engl J Med 344:276–285. doi:10.1056/NEJM200101253440407

    Article  PubMed  CAS  Google Scholar 

  2. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717. doi:10.1016/S0140-6736(05)66544-0

    Article  CAS  Google Scholar 

  3. Fisher B, Jeong JH, Bryant J et al (2004) Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 364:858–868. doi:10.1016/S0140-6736(04)16981-X

    Article  PubMed  CAS  Google Scholar 

  4. Rutqvist LE, Johansson H, Stockholm Breast Cancer Study Group (2007) Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncol 46:133–145

    Article  PubMed  CAS  Google Scholar 

  5. Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738–2746

    PubMed  CAS  Google Scholar 

  6. Hortobagyi GN, Kau SW, Buzdar AU et al (2004) What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis? J Clin Oncol 22:14s. doi:10.1200/JCO.2004.02.927. Abstract 585

    Article  CAS  Google Scholar 

  7. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (1998) Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351:1451–1467. doi:10.1016/S0140-6736(97)11423-4

    Article  Google Scholar 

  8. Fisher B, Dignam J, Bryant J, Wolmark N (2001) Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93:684–690. doi:10.1093/jnci/93.9.684

    Article  PubMed  CAS  Google Scholar 

  9. Wakeling AE, Valcaccia B, Newboult E, Green LR (1984) Non-steroidal anti-oestrogens—receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells. J Steroid Biochem 20:111–120. doi:10.1016/0022-4731(84)90197-3

    Article  PubMed  CAS  Google Scholar 

  10. Jordan VC (1994) Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Res Treat 31:41–52. doi:10.1007/BF00689675

    Article  PubMed  CAS  Google Scholar 

  11. Jordan VC (2006) The science of selective estrogen receptor modulators: concept to clinical practice. Clin Cancer Res 12:5010–5013. doi:10.1158/1078-0432.CCR-06-1136

    Article  PubMed  CAS  Google Scholar 

  12. Bryant HU, Dere WH (1998) Selective estrogen modulators: an alternative to hormone replacement therapy. Proc Soc Exp Biol Med 217:45–52

    PubMed  CAS  Google Scholar 

  13. Gottardis MM, Jordan VC (1988) Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48:5183–5187

    PubMed  CAS  Google Scholar 

  14. Osborne CK (1993) Mechanisms for tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism. J Steroid Biochem Mol Biol 47:83–89. doi:10.1016/0960-0760(93)90060-A

    Article  PubMed  CAS  Google Scholar 

  15. Osborne CK, Coronado E, Allred DC et al (1991) Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst 83:1477–1482. doi:10.1093/jnci/83.20.1477

    Article  PubMed  CAS  Google Scholar 

  16. Peto R, Davies C, on behalf of the ATLAS Collaboration (2007) ATLAS (adjuvant tamoxifen, longer against shorter): international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11 500 women preliminary results. Breast Cancer Res Treat 106(Suppl 1). Abstract 48

    Google Scholar 

  17. Fletcher-Louis M, Ireland S (2000) Onkos study 48: breast cancer. Decision Resources, Waltham

    Google Scholar 

  18. Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081–1092. doi:10.1056/NEJMoa040331

    Article  PubMed  CAS  Google Scholar 

  19. Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62. doi:10.1016/S0140-6736(05)74803-0

    Article  PubMed  CAS  Google Scholar 

  20. Thürlimann B, on behalf of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747–2757. doi:10.1056/NEJMoa052258

    Google Scholar 

  21. Goss PE, Ingle JN, Martino S et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793–1802. doi:10.1056/NEJMoa032312

    Article  PubMed  CAS  Google Scholar 

  22. Goss PE, Ingle JN, Martino S et al (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262–1271

    Article  PubMed  CAS  Google Scholar 

  23. Ingle JN, Tu D, Pater JL et al (2006) Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 99:295–300. doi:10.1007/s10549-006-9207-y

    Article  PubMed  CAS  Google Scholar 

  24. Goss PE, Ingle JN, Palmer MJ et al (2005) Updated analysis of NCIC CTG MA.17 (letrozole vs placebo to letrozole vs placebo) post unblinding. Breast Cancer Res Treat 94(Suppl 1):S10. Abstract 16

    Google Scholar 

  25. Robert NJ, Goss PE, Ingle JN et al (2006) Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs placebo) post unblinding. J Clin Oncol 24:18s. doi:10.1200/JCO.2005.04.1764. Abstract 550

    Article  CAS  Google Scholar 

  26. Ingle J, Tu D, Shepherd L et al (2006) NCIC CTG MA.17: intent to treat analysis (ITT) of randomized patients after a median follow-up of 54 months. J Clin Oncol 24:18s. doi:10.1200/JCO.2005.04.1053. Abstract 549

    Article  CAS  Google Scholar 

  27. Wasan KM, Goss PE, Pritchard PH et al (2005) The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 16:707–715. doi:10.1093/annonc/mdi158

    Article  PubMed  CAS  Google Scholar 

  28. Perez EA, Josse RG, Pritchard KI et al (2006) Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a comparison study to NCIC CTG MA.17. J Clin Oncol 24:1–7. doi:10.1200/JCO.2005.03.7234

    Article  Google Scholar 

  29. Brufsky A (2006) Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update. Semin Oncol 33((2 Suppl 7)):S13–S17. doi:10.1053/j.seminoncol.2006.03.022

    Article  PubMed  CAS  Google Scholar 

  30. Bundred N, Campbell I, Coleman R et al (2006) Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZO-FAST study). Eur J Cancer Suppl 4:48. Abstract 12

    Article  Google Scholar 

  31. Aapro M, Abrahamsson PA, Body JJ et al (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19:420–432. doi:10.1093/annonc/mdm442

    Article  PubMed  CAS  Google Scholar 

  32. Hadji P, Body JJ, Aapro MS et al. (2008) Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol. Epub ahead of print 29 April

  33. Whelan TJ, Goss PE, Ingle JN et al (2005) Assessment of quality of life in MA.17: a randomized, placebo controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 23:6931–6940. doi:10.1200/JCO.2005.11.181

    Article  PubMed  CAS  Google Scholar 

  34. Muss HB, Tu D, Ingle JN et al (2006) The benefits of letrozole in postmenopausal women with early stage breast cancer who have had five years of tamoxifen are independent of age. Breast Cancer Res Treat 100(Suppl 1). Abstract 102

    Google Scholar 

  35. Goss PE, Ingle JN, Martino S et al (2007) Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol 25:1–6. doi:10.1200/JCO.2006.07.7677

    Article  Google Scholar 

  36. Jakesz R, Samonigg H, Greil R et al (2005) Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Study Group Trial 6a (ABSCG-6a). J Clin Oncol 23:10s. Abstract 527

    Google Scholar 

  37. Mamounas E, Jeong J-H, Wickerham L et al (2006) Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent-to-treat analysis of NSABP B-33. Breast Cancer Res Treat 100(Suppl 1). Abstract 49

    Google Scholar 

  38. Goldhirsch A, Glick JH, Gelber RD et al (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569–1583. doi:10.1093/annonc/mdi326

    Article  PubMed  CAS  Google Scholar 

  39. Rieber AG, Theriault RL (2005) Aromatase inhibitors in postmenopausal breast cancer patients. J Natl Compr Canc Netw 3:309–314

    PubMed  Google Scholar 

  40. Winer EP, Hudis C, Burstein HJ et al (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23:619–629. doi:10.1200/JCO.2005.09.121

    Article  PubMed  CAS  Google Scholar 

Download references

Financial disclosure/conflict of interest statement

The author of this article has no commercial associations (e.g., consultancies, stock ownership, equity business, patentlicensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted article. All funding sources supporting the work and all institutional or corporate affiliations of the authors are acknowledged.

Author information

Authors and Affiliations

  1. Massachusetts General Hospital Cancer Center, 55 Fruit Street, Lawrence House, LRH-302, Boston, MA, 02114, USA

    Paul E. Goss

Authors
  1. Paul E. Goss
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul E. Goss.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goss, P.E. Extending the benefits of adjuvant therapy in early HR+ breast cancer. Breast Cancer Res Treat 112 (Suppl 1), 45–52 (2008). https://doi.org/10.1007/s10549-008-0129-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-008-0129-8

Keywords

Search

Navigation